Holen Sie sich die Stockscreener-App
3.4956
2.92%
-0.1044
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$3.60
Offen:
$3.62
24-Stunden-Volumen:
1.34M
Relative Volume:
0.28
Marktkapitalisierung:
$438.31M
Einnahmen:
$41,000
Nettoeinkommen (Verlust:
$-88.09M
KGV:
-3.4426
EPS:
-1.0154
Netto-Cashflow:
$-67.55M
1W Leistung:
-1.27%
1M Leistung:
-22.85%
6M Leistung:
-3.98%
1J Leistung:
-32.79%
1-Tages-Spanne:
$3.4813
$3.68
1-Wochen-Bereich:
$3.4813
$4.04
52-Wochen-Spanne:
$2.90
$7.73
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.50 | 450.83M | 41,000 | -88.09M | -67.55M | -1.0154 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.22 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.63 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.02 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.96 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.43 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Sell |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-24 | Eingeleitet | Goldman | Neutral |
| 2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-11 | Eingeleitet | Guggenheim | Buy |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-11-12 | Bestätigt | B. Riley Securities | Buy |
| 2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
| 2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
| 2019-07-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Altimmune: The High Cost Of Going Solo (Rating Downgrade) (NASDAQ:ALT) - Seeking Alpha
Altimmune at Barclays Conference: Advancing Pemvidutide’s Potential By Investing.com - Investing.com Canada
Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat - Yahoo Finance
Aug Final Week: Is Altimmune Inc stock a value trap2026 Macro Impact & AI Driven Price Forecasts - baoquankhu1.vn
Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up - MarketBeat
Altimmune at Leerink Conference: Strategic Advances in MASH Treatment By Investing.com - Investing.com Canada
Altimmune Details Pemvidutide Phase III MASH Plans, Breakthrough Status at Citizens Conference - Yahoo Finance
ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns - MSN
Altimmune at The Citizens Life Sciences Conference: Strategic Insights on Pemvidutide - Investing.com
ALT: Pemvidutide advances to phase 3, targeting MASH with strong efficacy and best-in-class tolerability - TradingView
Fireside chat set for Leerink Global Healthcare Conference, Altimmune announces - Traders Union
Altimmune Bets Big on PEMB as Phase III Nears - TipRanks
Altimmune to start late-stage trial for MASH candidate this year - MSN
Altimmune CFO Weaver buys $17,700 in shares By Investing.com - Investing.com Australia
Altimmune joins Citizens Life Sciences Conference for fireside chat in Miami Beach - Traders Union
Altimmune CEO Durso buys $70,790 in shares - Investing.com India
Gregory Weaver Acquires 5,000 Shares of Altimmune (NASDAQ:ALT) Stock - MarketBeat
Altimmune (NASDAQ:ALT) CEO Acquires $70,800.00 in Stock - MarketBeat
Altimmune Inc (ALT) CEO Jerome Durso Increases Stake with Recent Insider Purchase - GuruFocus
Altimmune CFO Weaver buys $17,700 in shares - Investing.com
Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of "Hold" by Analysts - MarketBeat
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns - Stocktwits
Can Altimmune Inc. stock deliver surprise earnings beat2026 Volume Leaders & Weekly High Return Stock Forecasts - Naître et grandir
Altimmune (NASDAQ:ALT) Rating Lowered to Sell at Wall Street Zen - MarketBeat
History Review: Is Altimmune Inc a speculative investment2025 Investor Takeaways & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
ALT: Analyst Lowers Price Target While Maintaining Buy Rating | - GuruFocus
Altimmune (NASDAQ:ALT) Price Target Cut to $13.00 by Analysts at B. Riley Financial - MarketBeat
Altimmune (NASDAQ:ALT) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
B. Riley Adjusts Price Target on Altimmune to $13 From $18, Maintains Buy Rating - marketscreener.com
Altimmune, Inc. (NASDAQ:ALT) Q4 2025 Earnings Call Transcript - Insider Monkey
William Blair Maintains Market Perform on ALT (Altimmune, Inc.) March 2026 - Meyka
Altimmune Q4 Earnings Call Highlights - MarketBeat
Altimmune Inc (ALT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Fortification - GuruFocus
Altimmune (ALT) Advances Liver Disease Focus with Pemvidutide - GuruFocus
Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment - Stocktwits
William Blair reiterates Altimmune stock rating on trial data By Investing.com - Investing.com Nigeria
Altimmune Shares Fall After Q4 Results - marketscreener.com
William Blair reiterates Altimmune stock rating on trial data - Investing.com India
Altimmune Q4 2025 Earnings Call Transcript - MarketBeat
Altimmune (ALT) Shares Drop Despite Breakthrough Therapy Plans - GuruFocus
Altimmune (ALT) Q4 2025 Earnings Call Transcript - The Globe and Mail
Earnings call transcript: Altimmune Inc. misses Q4 2025 expectations, stock declines - Investing.com Nigeria
Altimmune Reports 2025 Financial Results and Clinical Trial Progress with New Partnerships Formed - geneonline.com
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates - Bitget
Altimmune earnings missed by $0.02, revenue fell short of estimates - Investing.com
Altimmune (ALT) Reports Increased Revenue and Advances in Liver Disease Treatment - GuruFocus
ALTIMMUNE ($ALT) Releases Q4 2025 Earnings - Quiver Quantitative
Altimmune stock edges down on fourth quarter earnings miss By Investing.com - Investing.com UK
Altimmune stock edges down on fourth quarter earnings miss - Investing.com India
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Altimmune Inc-Aktie (ALT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Durso Jerome Benedict | President and CEO |
Mar 06 '26 |
Buy |
3.54 |
20,000 |
70,790 |
32,500 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '26 |
Option Exercise |
0.00 |
7,775 |
0 |
115,153 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '26 |
Option Exercise |
0.00 |
9,275 |
0 |
104,670 |
| Garg Vipin K | Director |
Jan 30 '26 |
Option Exercise |
0.00 |
26,775 |
0 |
429,225 |
| Jordt Raymond M | Chief Business Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
69,765 |
| Garg Vipin K | Director |
Jan 27 '26 |
Option Exercise |
0.00 |
41,200 |
0 |
420,348 |
| Roberts M Scot | Chief Scientific Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
100,143 |
| Jordt Raymond M | Chief Business Officer |
Jan 25 '26 |
Option Exercise |
0.00 |
14,600 |
0 |
57,770 |
| Garg Vipin K | Director |
Jan 25 '26 |
Option Exercise |
0.00 |
42,050 |
0 |
397,132 |
| Roberts M Scot | Chief Scientific Officer |
Jan 25 '26 |
Option Exercise |
0.00 |
14,600 |
0 |
88,666 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):